According to GlobalData’s Drugs Database, the schizophrenia market remains dominated by dopamine-targeted mechanisms, such as ...

Drugs such as Cobenfy could reshape the antipsychotic market, providing a more nuanced range of patient options.

Research has shown links between stereotypic behaviors and different levels of dopamine, GABA, acetylcholine, and ghrelin ...

The pharmacotherapy of schizophrenia is currently dominated by atypical antipsychotics that primarily target dopaminergic signalling, the dysregulation of which has long been considered to have a ...